ClinicalTrials.gg
CompletedNCT03830762XanaHESUpdated Jan 22, 2025

Xanamem™ in Healthy Elderly Subjects

A Phase 1 interventional study of Xanamem and Matching Placebo in Safety, Peripheral Neuropathy and Cortisol, sponsored by Actinogen Medical. Completed at 1 site in Australia. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-22.

Primary conditionSmall Fiber NeuropathyRegistry: Peripheral Nervous System DiseasesReclassifiedWhy we changed it
Registry
Peripheral Nervous System Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Small Fiber Neuropathy
Why
  1. The study's listed conditions name Small Fiber Neuropathy, a narrower term within Peripheral Nervous System Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Actinogen Medical · Phase 1, Interventional, and Other

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Study summary

Xanamem™ is being developed as a potential drug for Alzheimer's disease. This study drug has been designed to change the cortisol levels in the brain. Cortisol is a naturally occurring hormone in the body. It is believed that reducing the level of cortisol will be a benefit in the treatment of Alzheimer's disease.

The XanaHES study is testing the safety and tolerability of Xanamem. It is planned to enrol approximately 84 participants, male and female aged from 50 to 75 who are in good health, in the study at 1 centre in Australia.

The XanaHES Phase I study is a single-blind study. Subjects will be randomised to receive either 20mg once daily Xanamem or Placebo in cohort 1. Once all subjects have completed the study treatment of 12 weeks, a dose escalation committee will decide if a new cohort, cohort 2, with 30mg once daily vs placebo is started.

Read the detailed description

This is a Phase I, randomised, single-centre, single-blind, placebo-controlled study to assess the safety, tolerability of oral Xanamem once daily in healthy elderly subjects.

It is planned to randomise approximately 84 subjects, 42 in each cohort, at a single site in Australia.

Cohort 1 starts with a 20mg QD dose vs matching placebo. A Dose Escalation Committee will review the results from cohort 1 and provide a recommendation to proceed with Cohort 2 randomisation which involves a dose escalation to 30mg.

At the Baseline visit (Week 0), eligible subjects will be randomised on a 30:12 ratio to receive either Xanamem administered orally QD (treatment group) or matching placebo (placebo group). Subjects will return to the study site for visits at Week 2, Week 4, Week 6, Week 8, Week 10, End of Treatment (Week 12) and Follow-up (4 weeks post last dose of study drug) visits, at which study assessments will be performed.

Ad hoc telephone contact may also occur at any other time-point throughout the study, if deemed necessary by the investigator/study nurse, or if the subject wishes to report an adverse event (AE).

Subjects will be interviewed and examined at the study site at each visit and will complete a variety of questionnaires, routine safety evaluations and nerve function tests.

A central reader will review every Nerve Function Monitoring (NFM) assessment performed for each subject for Potential Nerve Safety Signals (PNSS).

Optional cerebrospinal fluid (CSF) sampling will be performed at baseline and end of treatment visits for a small subgroup of subjects, who provide additional consent. Subjects who do not provide consent for this optional sub-study will still be eligible for the main study.

The overall study duration for an individual subject will be 17 to 20 weeks, including a screening period of up to 4 weeks, a single-blind treatment period of 12 weeks, and a follow-up period of 4 weeks. The total duration of the study is expected to be 1.5 years.

02

Conditions studied

  • Safety
  • Peripheral Neuropathy
  • Cortisol
  • Central Nervous System
  • Cognitive Function
  • Healthy Ageing
  • Small Fibre Neuropathy
  • Cerebrospinal Fluid
  • Electrocardiography

Browse trials for

Keywords

  • Actinogen
  • Xanamem
  • UE2343
  • Cortisol
  • 11β-HSD1
  • 11-beta-Hydroxysteroid Dehydrogenase Type 1
  • Healthy Ageing
  • Peripheral Neuropathy
  • Safety
  • Dose Escalation
  • Elderly
  • XanaHES
  • emestedastat
03

In context

Small Fiber Neuropathy Reclassified

50 studies on the registry are indexed under Small Fiber Neuropathy; 12 are open to participants now.

This study's enrollment of 42 is above the median of 31 across 31 interventional studies indexed under Small Fiber Neuropathy.

Browse Small Fiber Neuropathy studies →

Lead sponsor

Actinogen Medical is the lead sponsor of 6 studies on the registry; none are open to participants now.

Compared within Small Fiber Neuropathy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Nervous System Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Volunteers aged 50 to 75 years.
  2. Female subjects:

    1. women, defined as no menses for 12 months without an alternative medical cause. If there is any concern about the menopausal status of a prospective female subject, a follicle stimulating hormone test (FSH) should be requested to confirm post-menopausal status. Post-menopausal women confirmed by FSH level > 40 mIU/mL, will be confirmed by the local laboratory.
    2. Women of (WOCBP) must have a negative pregnancy test.
  3. Male Subjects:

    1. Who are sexually active, fertile men must use highly effective methods of from Day 1 until 3 months after last dose of study drug if their partners are WOCBP
    2. Who are permanently sterile or have had bilateral orchiectomy or bilateral vasectomy.
  4. No disease which may cause a peripheral neuropathy.
  5. No evidence of alcohol abuse (defined as greater than 21 standard units per week for males and greater than 14 standard units per week for females).
  6. Must provide written to participate in the study and be willing and able to participate for the maximum of 12 weeks of treatment and 16 weeks of site visits.

Exclusion criteria

Exclusion Criteria:

  1. abnormalities in vital signs (blood pressure, heart rate, respiration rate and oral temperature), as determined by the investigator.
  2. (BMI) > 38 kg/m2
  3. Clinically significant abnormal haematology, biochemistry and urine examination values, as determined by the investigator.
  4. Participants who have a history of liver disease, including fatty liver, or LFT elevations requiring investigation will not be eligible.
  5. Has had a significant systemic illness or infection within the past 4 weeks prior to randomisation, as determined by the investigator.
  6. Documented diagnosis of Type I or Type II diabetes.
  7. Has a history of disease directly related to the hypothalamus, the pituitary and/or the adrenal glands which affects the hypothalamic-pituitary-adrenal axis function.
  8. Has any uncontrolled clinical condition relating to glucose or lipid metabolism.
  9. Subjects with clinical evidence of peripheral neuropathy or historical evidence of clinically significant nerve conduction abnormalities. Clinical evidence of neuropathy.
  10. Clinically significant (ECG) abnormalities, including > 450 msec (male) and > 470 msec (female), following ECG tracings at Screening.
  11. Use of any prohibited medication.
  12. Participation in another clinical study of a drug or device whereby the last drug/device administration is within 60 days of Screening.
  13. Inability to communicate well with the investigator (i.e. language problem, non-fluent English [as questionnaires and study drug label will be provided in English only], poor mental development or impaired cerebral function).
  14. Subject will undergo the Columbia Suicide Severity Rating Scale (CSSRS), Toronto Clinical Neuropathy Score (TCNS), EuroQoL Health Related Quality of Life - 5 Dimensions - 5 Levels (EQ-5D-5L), and Cogstate Test Battery at the indicated time-points to avoid uncontrolled learning effects. Subjects who need to perform these tests externally to and in parallel with this study will be excluded.
  15. For subjects that consent, and are subsequently accepted for enrolled into, the CSF optional sub-study, subjects must have no to the lumbar puncture procedure as assessed by the Principal Investigator. Such contraindications may include uncontrolled bleeding abnormalities or skin or spine abnormalities.
  16. Positive testing for (HIV), surface antigen (HBsAg), or antibodies (HCV). Subjects returning a positive result will be managed by the site in line with standard care.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Cohort 1 / Cohort 2 (Active)

    20mg or 30mg capsules of Xanamem respectively, to be administered PO once daily.

    Drug: Xanamem

  • Placebo comparator
    Cohort 1 / Cohort 2 (Placebo)

    Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily.

    Drug: Matching Placebo

Interventions

  • DrugUE2343Studies of UE2343UE2343 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral Xanamem capsules 20mg or 30mg, administered PO once daily. Xanamem is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343.

    Also known as: UE2343

  • DrugMatching Placebo

    Matching placebo which is identical in appearance to the test product (20mg, 30mg Xanamem™ QD) except that it contains no active ingredient.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (AEs)

    The number, type, and severity of treatment-emergent adverse events (AEs) that are reported from Screening Visit to Follow-up Visit will be collected and evaluated.

    Time frame: 20 Weeks (Screening up to Week 16 Follow-Up [4 Weeks Post Last Dose of Study Drug ± 4 Days])

  2. Incidence of Clinically Significant Changes in Serum Biomarker Levels in a Standard Serum Chemistry Panel

    Collection of blood samples for clinical laboratory testing to assess any clinically significant changes in standard serum chemistry measures.

    Time frame: Screening up to Week 16 (Follow-Up [4 Weeks Post Last Dose of Study Drug ± 4 Days])

  3. Incidence of Clinically Significant Laboratory Haematological Biomarker Levels in a Standard Haematology Panel.

    Collection of blood samples for clinical laboratory testing to assess any clinically significant changes in standard haematology measures.

    Time frame: Screening up to Week 16 (Follow-Up [4 Weeks Post Last Dose of Study Drug ± 4 Days])

  4. Incidence of Clinically Significant Changes or Abnormalities Following Physical Examination

    Evaluation of any clinically significant changes or abnormalities reported following a standard Physical Examination.

    Time frame: Screening up to Week 16 (Follow-Up) and Unscheduled Safety Visit throughout duration of study up to Week 16 (Follow-Up Visit [4 Weeks Post Last Dose of Study Drug ± 4 Days])

  5. Nerve Conduction Assessments

    Nerve Conduction assessments will be used to detect presence and severity of nerve damage.

    Time frame: Screening up to Week 16 (Follow-Up Visit [4 Weeks Post Last Dose of Study Drug ± 4 Days])

  6. Neuropathy Total Symptom Score-6 (NTSS-6)

    Changes in the Neuropathy Total Symptom Score (NTSS-6) administered by a physician to assess a subjects' medical history. Each item will also be graded for its frequency and intensity, adding up to a total score from "0" to "21.96" points. A total score of \> 6 would exclude the subject from the study.

    Time frame: Screening, Week 2, Week 4, Week 8, Week 12 (End of Treatment), Week 16 (Follow-Up) and Telephone Contact (Ad Hoc)

  7. Toronto Clinical Neuropathy Score (TCNS)

    Changes in Toronto Clinical Neuropathy Score (TCNS) to detect for neuropathy out of a total score of 19; scales are defined as follows: 0-5 = no neuropathy; 6-8 = mild neuropathy; 9-11 = moderate neuropathy; ≥ 12 = severe neuropathy.

    Time frame: Screening, Week 2, Week 4, Week 8, Week 12 (End of Treatment), Week 16 (Follow-Up) and Telephone Contact (Ad Hoc)

  8. Skin Biopsy

    A 3mm skin sample will be taken via skin punch biopsy to detect intra-epidermal nerve fiber density; this allows for the objectification and quantification of a small-fiber neuropathy.

    Time frame: At Baseline and Week 12 (End of Treatment)

  9. Quantitative Sensory Testing (QST)

    Thermal sensory testing using Quantitative Sensory Testing (QST) for cold, warm and heat pain to detect peripheral nerve disorders.

    Time frame: Screening up to Week 16 (Follow-Up Visit [4 Weeks Post Last Dose of Study Drug ± 4 Days])

  10. Columbia Suicide Severity Rating Scale (CSSRS)

    Any change in Columbia Suicide Severity Rating Scale (CSSRS) will assess suicidal ideation and behaviour. * Suicidal ideation score: Any score greater than 0 is important and may indicate the need for mental health intervention. * Suicidal ideation intensity rating: The five intensity item scores create a total score (range 0 to 25) to represent the intensity rating, if the patient did not endorse any suicidal ideation the intensity rating is 0.

    Time frame: Screening, Baseline, Week 2, Week 4, Week 8, Week 12 (End of Treatment), Week 16 (Follow-Up)

  11. Electrocardiogram (ECG)

    Any clinically significant electrocardiogram (ECG) abnormalities will be recorded, including corrected QT interval (QTc) of \> 500 msec.

    Time frame: Screening up to Week 16 (Follow-Up Visit [4 Weeks Post Last Dose of Study Drug ± 4 Days])

Other outcomes

  1. Detection Test (Cogstate Test Battery)

    Changes in Cogstate Detection test is a measure of simple reaction time and has been shown to provide a valid assessment of psychomotor function. For this test, the subject must press a "YES" response key as soon as they detect an event (i.e. a card turning face up presented in the centre of the computer screen). The software measures the response time to detect each event.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12 (End of Treatment), Week 16 (Follow-Up)

  2. Identification Test (Cogstate Test Battery)

    Changes in the Cogstate Identification test is a measure of choice reaction time and has been shown to provide a valid assessment of visual attention. In this test an event (a card turning face up) occurs in the centre of the computer screen and the subject must decide "YES" or "NO" as to whether this event meets a predefined and unchanging criterion (is the colour of the card red?). The software measures the speed and accuracy of each response.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12 (End of Treatment), Week 16 (Follow-Up)

  3. One Back Working Memory Test (Cogstate Test Battery)

    Changes in Cogstate the Cogstate One Back memory test is a valid measure of working memory. On this test the subject is shown a single stimulus in the centre of the computer screen (a card turns face up). They must decide "YES" or "NO" as to whether the current card matches the card that had been seen on the immediately previous trial. The software measures the speed and accuracy of each response.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12 (End of Treatment), Week 16 (Follow-Up)

  4. One Card Learning Test (Cogstate Test Battery)

    Changes in Cogstate the One Card Learning test is a continuous visual recognition learning test that assesses visual learning within a pattern separation model. The One Card Learning test has been shown to be a valid test of learning and memory. In this test the participant must attend to the card in the centre of the screen and respond to the question "have you seen this card before in this test?" If the answer was yes, participants are instructed to press the "YES" button, and the "NO" button if the answer is no. Normal playing cards are displayed (without joker cards). In this test, six cards are drawn at random from the deck and are repeated throughout the test. These four cards are interspersed with distractors (non-repeating cards). The test ends after 50 trials, without rescheduling for post-anticipatory correct trials. The primary performance measure for this test is the proportion of correct answers (accuracy), which is normalized using an arcsine square root transformation.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12 (End of Treatment), Week 16 (Follow-Up)

  5. Continuous Paired Associate Learning Test ([CPAL; Paired Associate Learning] Cogstate Test Battery)

    Changes in Cogstate the Continuous Paired Associate Learning test is a measure of visual associate memory and uses a well-validated paired associate learning paradigm in which the subject must learn the locations of a number of amoeba-like shapes on the computer screen. Finding the correct location for all patterns in the set is defined as a learning trial. There are six learning trials. A single trial delayed recall condition is available for this test after a 10-30-minute delay. The software records each move as an error or as a correct move.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12 (End of Treatment), Week 16 (Follow-Up)

  6. Pharmacokinetics Blood Sample Assessment

    Changes in area under the plasma concentration versus time curve (AUC). Peripheral pharmacokinetic (PK) blood samples will be taken from all enrolled subjects.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12 (End of Treatment), Week 16 (Follow-Up) and Unscheduled Safety Visit throughout duration of study up to Follow-Up Visit (4 Weeks Post Last Dose of Study Drug ± 4 Days)]

  7. Cortisol Concentration

    Changes in peripheral cortisol concentration levels with analysis of Pharmacokinetics (PK) blood samples.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12 (End of Treatment) and Week 16 (Follow-Up)

  8. Optional Cerebrospinal Fluid Assessment

    An optional CSF assessment will be offered to willing participants to detect changes in CSF levels from a minimum of 8 enrolled subjects, 4 subjects from each cohort, randomised to active treatment, for those who consent to take part in the CSF sub-study. Two CSF samples will be taken End of Treatment (EOT) at Week 12 visit, one for primary analysis and one sample to be retained for back-up purposes.

    Time frame: Week 12 (End of Treatment)

  9. Health Related Quality of Life: EQ-5D-5L

    Overall Health Related Quality of Life (HRQoL) will be assessed by EuroQoL Health Related Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L). The EQ-5D-5L is a standardized, participant-rated questionnaire for use as a measure of health outcomes. The EQ 5D-5L includes 2 components: the EQ-5D-5L descriptive system and the visual analogue scale (VAS). The EQ-5D-5L descriptive system provides a profile of the participant's health state in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, the participant is instructed to choose one of 5 levels that best describes their health on that day: "no problem" (1), "slight" (2), "moderate" (3), "severe" (4), or "unable/extreme" (5). The VAS is the participant's rating of their health on a scale of 0 "worst health you can imagine" to 100 "best health you can imagine".

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12 (End of Treatment) and Week 16 (Follow-Up)

07

Study locations

1 site
  • Linear Clinical Research
    Perth, Western Australia 6009, Australia
08

References and documents

Publications

  • Webster SP, McBride A, Binnie M, Sooy K, Seckl JR, Andrew R, Pallin TD, Hunt HJ, Perrior TR, Ruffles VS, Ketelbey JW, Boyd A, Walker BR. Selection and early clinical evaluation of the brain-penetrant 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor UE2343 (Xanamem). Br J Pharmacol. 2017 Mar;174(5):396-408. doi: 10.1111/bph.13699. Epub 2017 Jan 25. PubMed 28012176 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Dec 2019, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2019
First posted
Feb 5, 2019
StartActual
Jan 21, 2019
Primary completionActual
Dec 7, 2019
CompletionActual
Jan 7, 2020
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03830762
Lead sponsor
Actinogen Medical
Collaborators
ICON plc
Responsible party
Sponsor
First posted
Feb 5, 2019
Start date
Jan 21, 2019
Primary completion
Dec 7, 2019
Completion
Jan 7, 2020
Last update
Jan 22, 2025

Study contacts

Bill Ketelbey, MD
study chair · Actinogen Medical

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: UE2343

Start the discussion